Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eris Lifesciences is positioning itself to capture a significant share of India’s human insulin market following Novo Nordisk ...

“The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, ...

Wegovy, a brand name for semaglutide, is a GLP-1 inhibitor medication that targets the parts of the brain that regulate ...

You might have seen people talking about a 'golden dose' on social media in regards to weight loss jabs, but what exactly is ...

If you’re one of the many people using Ozempic (semaglutide) to manage type 2 diabetes or for weight loss under medical ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

FAT jabs are not a “quick fix” and patients must be followed up for at least a year to keep the weight off, the NHS watchdog ...

Three new studies suggest that Ozempic and related diabetes and weight loss drugs may help protect the brain from strokes.

A lot of people are trying to lose weight for a healthier life, a better appearance or self-satisfaction — but losing weight ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

A doctor has issued a warning to people who use weight loss jabs over the 'golden dose'. The use of GLP-1 medication, such as ...